FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274042394> ?p ?o ?g. }

• W2274042394 abstract "Although there is no standard treatment for recurrent glioblastoma, prospective data in selected patients have suggested the usefulness of bevacizumab. We report our single center experience with bevacizumab in a cohort of patients treated for a relapsing glioblastoma.We performed a retrospective analysis of consecutive patients treated with bevacizumab for a relapsed glioblastoma, between 2008 and 2013. Tumor responses, toxicities, time to progression and overall survival rates were analyzed.Thirty-five consecutive patients were identified. They were treated with bevacizumab 10mg/kg biweekly, associated with irinotecan (n=29; 84%), temozolomide (n=3; 9%) or as single agent (n=3; 9%) for a glioblastoma relapsing after chemoradiation (n=29) or after first line temozolomide only because of a poor general health status or because of multifocal tumor. Two (6%), 28 (80%) and five (14%) patients presented with Recursive Partitioning Analysis (RPA) III, IV and V-VI, respectively. After 2-3 months of treatment, median dose of prednisolone per patient was decreased three times. Clinical improvements or stability were reported in eight (23%) and 17 patients (49%). The best tumor response was partial response in 14 patients (40%), stable disease in nine patients (26%) and tumor progression in 11 patients (31%). Toxicities requiring treatment disruption were reported in five patients (14%). Median survival was 18.4 months (5-41 months). Median time interval between bevacizumab initiation and its disruption because of clinical/radiological progression and/or toxicity was 5.0 months (0.6-21.4 months). Median survival from bevacizumab initiation was 8.1 months (1.4-34 months).This single center retrospective experience suggests that bevacizumab is active for recurrent glioblastoma, in a series of poorly selected patients. Median survival times were in the range of those reported in therapeutic trials. This study questions the validity of usual predictive factors in the era of bevacizumab." @default.
• W2274042394 created "2016-06-24" @default.
• W2274042394 creator A5001628805 @default.
• W2274042394 creator A5006893068 @default.
• W2274042394 creator A5014705261 @default.
• W2274042394 creator A5015455151 @default.
• W2274042394 creator A5018050846 @default.
• W2274042394 creator A5038769248 @default.
• W2274042394 creator A5058771570 @default.
• W2274042394 creator A5069608529 @default.
• W2274042394 creator A5073239916 @default.
• W2274042394 creator A5074927146 @default.
• W2274042394 creator A5075759968 @default.
• W2274042394 creator A5083227902 @default.
• W2274042394 date "2016-05-01" @default.
• W2274042394 modified "2023-10-18" @default.
• W2274042394 title "Expérience monocentrique d’un traitement par bévacizumab dans la prise en charge des glioblastomes récidivant" @default.
• W2274042394 cites W1567412466 @default.
• W2274042394 cites W1862835589 @default.
• W2274042394 cites W2009032810 @default.
• W2274042394 cites W2025446299 @default.
• W2274042394 cites W2030250579 @default.
• W2274042394 cites W2044538065 @default.
• W2274042394 cites W2066261700 @default.
• W2274042394 cites W2096800614 @default.
• W2274042394 cites W2103630928 @default.
• W2274042394 cites W2103719491 @default.
• W2274042394 cites W2116575184 @default.
• W2274042394 cites W2116891323 @default.
• W2274042394 cites W2118915687 @default.
• W2274042394 cites W2124736921 @default.
• W2274042394 cites W2127745545 @default.
• W2274042394 cites W2132697290 @default.
• W2274042394 cites W2156330848 @default.
• W2274042394 cites W2158681922 @default.
• W2274042394 cites W2165772224 @default.
• W2274042394 cites W2171714209 @default.
• W2274042394 doi "https://doi.org/10.1016/j.lpm.2015.06.018" @default.
• W2274042394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26916405" @default.
• W2274042394 hasPublicationYear "2016" @default.
• W2274042394 type Work @default.
• W2274042394 sameAs 2274042394 @default.
• W2274042394 citedByCount "1" @default.
• W2274042394 countsByYear W22740423942016 @default.
• W2274042394 crossrefType "journal-article" @default.
• W2274042394 hasAuthorship W2274042394A5001628805 @default.
• W2274042394 hasAuthorship W2274042394A5006893068 @default.
• W2274042394 hasAuthorship W2274042394A5014705261 @default.
• W2274042394 hasAuthorship W2274042394A5015455151 @default.
• W2274042394 hasAuthorship W2274042394A5018050846 @default.
• W2274042394 hasAuthorship W2274042394A5038769248 @default.
• W2274042394 hasAuthorship W2274042394A5058771570 @default.
• W2274042394 hasAuthorship W2274042394A5069608529 @default.
• W2274042394 hasAuthorship W2274042394A5073239916 @default.
• W2274042394 hasAuthorship W2274042394A5074927146 @default.
• W2274042394 hasAuthorship W2274042394A5075759968 @default.
• W2274042394 hasAuthorship W2274042394A5083227902 @default.
• W2274042394 hasConcept C121608353 @default.
• W2274042394 hasConcept C126322002 @default.
• W2274042394 hasConcept C141071460 @default.
• W2274042394 hasConcept C2776694085 @default.
• W2274042394 hasConcept C2777389519 @default.
• W2274042394 hasConcept C2777802072 @default.
• W2274042394 hasConcept C2780259306 @default.
• W2274042394 hasConcept C526805850 @default.
• W2274042394 hasConcept C71924100 @default.
• W2274042394 hasConcept C90924648 @default.
• W2274042394 hasConceptScore W2274042394C121608353 @default.
• W2274042394 hasConceptScore W2274042394C126322002 @default.
• W2274042394 hasConceptScore W2274042394C141071460 @default.
• W2274042394 hasConceptScore W2274042394C2776694085 @default.
• W2274042394 hasConceptScore W2274042394C2777389519 @default.
• W2274042394 hasConceptScore W2274042394C2777802072 @default.
• W2274042394 hasConceptScore W2274042394C2780259306 @default.
• W2274042394 hasConceptScore W2274042394C526805850 @default.
• W2274042394 hasConceptScore W2274042394C71924100 @default.
• W2274042394 hasConceptScore W2274042394C90924648 @default.
• W2274042394 hasLocation W22740423941 @default.
• W2274042394 hasLocation W22740423942 @default.
• W2274042394 hasOpenAccess W2274042394 @default.
• W2274042394 hasPrimaryLocation W22740423941 @default.
• W2274042394 hasRelatedWork W1998784751 @default.
• W2274042394 hasRelatedWork W2005124660 @default.
• W2274042394 hasRelatedWork W2024891581 @default.
• W2274042394 hasRelatedWork W2052928060 @default.
• W2274042394 hasRelatedWork W2169869816 @default.
• W2274042394 hasRelatedWork W2234353674 @default.
• W2274042394 hasRelatedWork W2276184886 @default.
• W2274042394 hasRelatedWork W2603294482 @default.
• W2274042394 hasRelatedWork W2913173828 @default.
• W2274042394 hasRelatedWork W4254526441 @default.
• W2274042394 isParatext "false" @default.
• W2274042394 isRetracted "false" @default.
• W2274042394 magId "2274042394" @default.
• W2274042394 workType "article" @default.